Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity

30 Mar 2015

Abstract excerpt

Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors. Imatinib also has efficacy against various pathogens, including pathogenic mycobacteria, where it decreases bacterial load in mice, albeit at doses below those used for treating cancer. We report that imatinib at such low...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Mast cells and histamine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25822986
DOI: 10.1371/journal.ppat.1004770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial ImmunityPMID 25822986Read ↗

The host-directed therapeutic imatinib mesylate accelerates immune responses to <i>Mycobacterium marinum</i> infection and limits pathology associated with granulomasSemantic proximity Read ↗

Transient activation of hematopoietic stem and progenitor cells by IFNγ during acute bacterial infection.Semantic proximity Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.Semantic proximity Read ↗

Inhibitory effect of imatinib on normal progenitor cells in vitroSemantic proximity Read ↗

Imatinib for systemic mast-cell disease.Semantic proximity Read ↗

CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemiaSemantic proximity Read ↗

The CML stem cell: Evolution of the progenitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.